Emphysema :: Retinoids, vitamin a – no help for emphysema patients
Retinoids, a derivative of vitamin A, may provide little clinical benefit for patients with emphysema, shows a new study.
Placebo
Apnea :: Research questions use of sleep meds for patients with apnea
New research reported in the journal CHEST shows that prescription sleep aids may do little to improve the use of continuous positive airway pressure among patients with obstructive sleep apnea. The study found that patients with OSA who were given prescription sleep aids were no more likely to use their CPAP machines than patients with OSA taking a placebo.
Restless Legs Syndrome :: Boehringer Ingelheim?s pramipexole for the treatment of Restless Legs Syndrome RLS
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the treatment of moderate to severe primary Restless Legs Syndrome (RLS).1 This is an important milestone for pramipexole (Mirapexin? / Sifrol? / Mirapex?), which was already approved throughout the European Union in April 2006 for this second indication.
Rheumatoid Arthritis :: ORENCIA, abatacept demonstrate continued efficacy in adults with rheumatoid arthritis
Bristol-Myers Squibb Company (NYSE: BMY) today announced that two-year data from three Phase III pivotal trials demonstrate the long-term efficacy of ORENCIA? (abatacept) in adult patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate and TNF antagonists. The data also demonstrate that ORENCIA provided clinically meaningful improvements in multiple aspects of health-related quality of life and physical function, sustained improvements in pain and had a consistent safety and tolerability profile through two years of treatment. These data will be presented at the upcoming 2006 American College of Rheumatology (ACR) Annual Scientific Meeting.
ADHD :: Study Evaluates Two Medications for ADHD
University of Illinois at Chicago researchers are comparing two drugs commonly used to treat attention deficit hyperactivity disorder to determine if genetic factors predict which children will respond to either or both drugs.
Osteoarthritis :: Prexige in the European Union as a new treatment option for osteoarthritic pain
Novartis announced today that Prexige? (lumiracoxib), an oral selective COX-2 inhibitor anti-inflammatory drug, has been cleared for approval in the European Union as a new treatment option for patients suffering from osteoarthritis. This is the most common form of arthritis and a leading cause of chronic pain[2].
Health :: FDA issues approvable letter for Entereg for POI
GlaxoSmithKline (NYSE: GSK) and Adolor Corporation (Nasdaq: ADLR) announced that the Food and Drug Administration (FDA) has issued a letter stating that the new drug application (NDA) for Entereg (alvimopan 12mg) for the management of post operative ileus (POI) is approvable. The FDA has requested 12-month safety data, including analysis of serious cardiovascular events, from study 014 (767905/014), an ongoing safety study in opioid-induced bowel dysfunction (OBD). The FDA also requested a risk management plan as part of the submission.
Depression :: New treatment strategy for the prevention of recurrent depression
Some patients who experience recurrent depression may benefit from long-term maintenance treatment with anti-depressant medication, according to a new study led by a Virginia Commonwealth University researcher.
Erectile Dysfunction :: Levitra, vardenafil treated erectile dysfunction effectively
Clinical data demonstrated continued efficacy and tolerability of LEVITRA in men with ED and high blood pressure, diabetes and/or dyslipidemia, including high cholesterol. LEVITRA(R) (vardenafil HCl), is effective at first dose with continued success in treating erectile dysfunction (ED) in men with associated medical conditions that affect the cardiovascular system. These conditions included high blood pressure, diabetes and/or dyslipidemia, which includes high cholesterol and other lipid abnormalities. These data were presented today at the Sexual Medicine Society of North America (SMSNA) Fall meeting and published in the November issue of the International Journal of Clinical Practice.
Nutrition :: Coenzyme Q10 – Should you take this supplement?
You may have heard claims that the supplement coenzyme Q10 can lower blood pressure, boost the immune system and improve certain heart diseases. There are also claims it can help fight cancer, Parkinson’s disease, wrinkles, diabetes, gum diseases and many other problems.